Literature DB >> 3760320

Prognostic evaluation in meningococcal disease. A retrospective study of 115 cases.

B Gårdlund.   

Abstract

A retrospective study of the medical records of 115 consecutive cases of meningococcal disease with 11 fatalities was carried out in order to evaluate the power of 15 clinical and laboratory variables available on admission in predicting a fatal outcome. On linear discriminant analysis, six variables showed a significant discriminating power in predicting death: low systolic blood pressure, low platelet count, extensive petechiae, high body temperature, low CSF polynuclear cell count and absence of meningism. From a stepwise linear discriminant analysis, two alternative procedures for prognostic evaluation were derived. If a large high risk group is accepted which will include practically all patients at risk of death, a prognostic evaluation based only on systolic blood pressure on admission is sufficient. Alternatively, if unconventional, potentially hazardous therapy is considered for high risk patients, a small high risk group may be defined. Patients with systolic blood pressure less than 100 mm Hg, platelet count less than or equal to 125 X 10(9)/l and body temperature greater than 39 degrees on admission constitute a small group with a very high mortality. A similar risk group was defined if platelet count less than or equal to 125 X 10(9)/l was substituted for extensive petechiae. The advantage of the latter procedure is that only a simple bedside examination is required for the prognostic evaluation.

Entities:  

Mesh:

Year:  1986        PMID: 3760320     DOI: 10.1007/bf00261740

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  8 in total

1.  Plasmapheresis for meningococcemia with disseminated intravascular coagulation.

Authors:  W B Scharfman; J R Tillotson; E G Taft; E Wright
Journal:  N Engl J Med       Date:  1979-05-31       Impact factor: 91.245

2.  Prognostic Factors in meningococcal disease.

Authors:  P M Niklasson; P Lundbergh; T Strandell
Journal:  Scand J Infect Dis       Date:  1971

3.  Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.

Authors:  B Osterud; T Flaegstad
Journal:  Thromb Haemost       Date:  1983-02-28       Impact factor: 5.249

4.  Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient.

Authors:  E R Stiehm; D S Damrosch
Journal:  J Pediatr       Date:  1966-03       Impact factor: 4.406

5.  Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange.

Authors:  B Bjorvatn; L Bjertnaes; H O Fadnes; T Flaegstad; T J Gutteberg; B E Kristiansen; J Pape; O P Rekvig; B Osterud; L Aanderud
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-11

6.  Prognostic factors in acute meningococcaemia.

Authors:  L S Lewis
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

Review 7.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

8.  Disseminated intravascular coagulation in patients with meningococcal infection: laboratory diagnosis and prognostic factors.

Authors:  H Vik-Mo; K Lote; A Nordøy
Journal:  Scand J Infect Dis       Date:  1978
  8 in total
  3 in total

Review 1.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Meningococcal disease: a comparison of eight severity scores in 125 children.

Authors:  H H Derkx; J van den Hoek; W K Redekop; R P Bijlmer; S J van Deventer; P M Bossuyt
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

3.  A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course.

Authors:  M Van Deuren; C Neeleman; L G Van 't Hek; J W Van der Meer
Journal:  Intensive Care Med       Date:  1998-02       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.